About capivasertib
AKT kinase inhibitor
Used for
- Treats certain hormone receptor-positive, HER2-negative advanced breast cancers with an AKT1, PIK3CA, or PTEN alteration, with fulvestrant.
Usual adult dose
400 mg by mouth twice daily for four days, followed by three days off each week, with fulvestrant; treatment may be adjusted for side effects.
Common side effects
- Diarrhea
- Skin rash
- Nausea
- High blood sugar
Important warnings
- Can cause severe diarrhea, dehydration, and kidney problems.
- May cause serious skin reactions; seek prompt medical assessment for severe rash.
- Blood sugar can rise substantially; monitoring is needed, especially with diabetes.
- May harm an unborn baby; effective contraception is recommended during treatment and for one month afterward.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for one month after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one month after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase capivasertib levels.
- Strong or moderate CYP3A inducers can reduce capivasertib levels.
- Avoid grapefruit and St John’s wort, which can affect drug levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.